check_circleStudy Completed
Maxillary Sinusitis
Bayer Identifier:
100569
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial to evaluate time to symptom relief and elimination of infecting bacteria in treating sinusitis with Avelox
Trial purpose
This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.
Key Participants Requirements
Sex
BothAge
18 YearsTrial summary
Enrollment Goal
192Trial Dates
June 2004 - January 2005Phase
Phase 4Could I Receive a placebo
NoProducts
Avelox (Moxifloxacin hydrochloride, BAY12-8039)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Buenos Aires (Capital Federal), 1416, Argentina | |
Completed | Longmont, 80501, United States | |
Completed | Buenos Aires, C1280AEB, Argentina | |
Withdrawn | Rochester, 14618, United States | |
Completed | Florencio Varela, 1888, Argentina | |
Completed | Rosario, 2000, Argentina | |
Completed | Richmond, 23229, United States | |
Completed | Córdoba, 5000, Argentina | |
Withdrawn | Córdoba, 5000, Argentina | |
Completed | Fresno, 93720, United States | |
Completed | Tucumán, 4000, Argentina | |
Completed | Greenville, 29607, United States | |
Completed | Lake Oswego, 97035, United States | |
Completed | Carrollton, 75010, United States | |
Completed | Yukon, 73099, United States | |
Withdrawn | San Francisco, 94102, United States | |
Completed | Florencio Varela, 1888, Argentina | |
Completed | Colorado Springs, 80909, United States | |
Completed | Bridgeport, 06606, United States | |
Completed | San Miguel de Tucumán, 4000, Argentina | |
Completed | Birmingham, 35215, United States | |
Withdrawn | Detroit, 48202, United States | |
Completed | Charlottesville, 22911, United States | |
Completed | Hoover, 35216-5453, United States | |
Completed | North Massapequa, 11758, United States | |
Completed | Winchester, 22601, United States | |
Completed | Searcy, 72143, United States | |
Completed | Shreveport, 71105, United States | |
Completed | Orangeburg, 29118, United States | |
Completed | Harrisburg, 17110, United States | |
Completed | Jonesboro, 72401, United States | |
Completed | Columbus, 43235, United States | |
Completed | Salt Lake City, 84102, United States | |
Completed | Riverside, 92506, United States | |
Completed | Jackson, 38301, United States | |
Completed | DeLand, 32720, United States | |
Completed | Oklahoma City, 73120, United States | |
Completed | Spokane, 99202-1334, United States | |
Withdrawn | Detroit, 48202, United States | |
Withdrawn | Argentina |
Primary Outcome
- Time to bacteriological eradication in those who are microbiologically valid for S. pneumoniae, M. catarrhalis, and H. influenzaedate_rangeTime Frame:Days 1, 2, 3 of treatmentenhanced_encryptionnoSafety Issue:
Secondary Outcome
- Patient-reported symptom improvement using SNOT-16 questionnairedate_rangeTime Frame:Up to End of Treatment (Day 10-13)enhanced_encryptionnoSafety Issue:
- Clinical Responsedate_rangeTime Frame:End of Treatmentenhanced_encryptionyesSafety Issue:
- Bacteriological Responsedate_rangeTime Frame:End of Treatmentenhanced_encryptionnoSafety Issue:
- Activity Impairment Assessment questionnairedate_rangeTime Frame:Up to End of Treatment (Day 10-13)enhanced_encryptionnoSafety Issue:
- Incidence of Premature Terminationdate_rangeTime Frame:Premature Terminationenhanced_encryptionyesSafety Issue:
- Adverse Events Collectiondate_rangeTime Frame:Up to End of Treatment (Day 10-13)enhanced_encryptionyesSafety Issue:
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
Non-randomizedBlinding
Open LabelAssignment
Single Group AssignmentTrial Arms
1